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Résumé en
anglais
Isolated growth hormone deficiency (IGHD) is a rare condition mainly caused by
mutations in GH1. The aim of this study was to assess the contribution of GHRHR
mutations to IGHD in an unusually large group of patients. All GHRHR coding exons
and flanking intronic regions were sequenced in 312 unrelated patients with
nonsyndromic IGHD. Functional consequences of all newly identified missense
variants were assessed in vitro (i.e., study of the expression of recombinant GHRHRs
and their ability to activate the cyclic adenosine monophosphate (cAMP) signaling
pathway). Genotype-phenotype correlation analyses were performed according to the
nature of the identified mutation. We identified 20 different disease-causing GHRHR
mutations (truncating and missense loss-of-function mutations), among which 15 are
novel, in 24 unrelated patients. Of note, about half (13/24) of those patients represent
sporadic cases. The clinical phenotype of patients with at least one missense GHRHR
mutation was found to be indistinguishable from that of patients with bi-allelic
truncating mutations. This study, which unveils disease-causing GHRHR mutations in
8% (24/312) of IGHD cases, identifies GHRHR as the second IGHD gene most
frequently involved after GH1. The finding that 8% of IGHD cases without GH1
mutations are explained by GHRHR molecular defects (including missense
mutations), together with the high proportion of sporadic cases among those patients,
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